Biotech Sector Sees Minimal IPO Activity in 2025

In 2025, the biotech, drug discovery, and medical device sectors have experienced notably low IPO activity, with only 16 funded U.S. startups debuting on Nasdaq or the New York Stock Exchange, according to Crunchbase data. This marks one of the slowest years for biotech IPOs in recent times.